Back to Search Start Over

Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible strategy?

Authors :
Bonomo, Pierluigi
Desideri, Isacco
Loi, Mauro
Lo Russo, Monica
Olmetto, Emanuela
Maragna, Virginia
Francolini, Giulio
Delli Paoli, Camilla
Grassi, Roberta
Pezzulla, Donato
Greto, Daniela
Meattini, Icro
Livi, Lorenzo
Source :
Oral Oncology. Nov2017, Vol. 74, p142-147. 6p.
Publication Year :
2017

Abstract

<bold>Objectives: </bold>The aim of our work was to report on the clinical outcome of a moderately hyprofractionated radiotherapy regimen in elderly patients affected by head and neck squamous cell carcinoma (HNSCC).<bold>Material and Methods: </bold>HNSCC aged ≥65 deemed unsuitable for curatively-intended concurrent chemo-radiotherapy or high-dose radiotherapy by clinical judgement were further evaluated with the Geriatric 8 (G8) questionnaire and Charlson comorbidity index (CCI). In case of a G8 score ≤14, a de-intensified radiation schedule of 40 Gy delivered in 16 fractions was prescribed.<bold>Results: </bold>Thirty-six patients were treated between 2011 and 2016. The median age of the cohort was 77.5 (range: 65-91 years) with a combined ECOG PS of 2-3 in 77.8% and CCI of ≥8 in 25% patients, respectively. At a median follow-up of 13 months (range 2-62 months), the 6-month and 1-year rates of loco-regional control and progression-free survival were 42%, 28% and 36% and 20%, respectively. At univariate analysis, log-rank test showed that age >75 years (p=0.036), worse PS (ECOG≥2; p=0.027), lower G8 score (<9; p=0.027) and PTV volume greater than 200 cc (p=0.038) had a significant correlation with PFS. The negative impact of the PTV volume on PFS was the only parameter confirmed in the multivariate analysis (HR 2.68; 95% CI: 1.24-5.81, p=0.013). No grade 4-5 toxicity was observed, while 13/36 patients (36%) had G3 acute side effects.<bold>Conclusion: </bold>The hypofractionated radiation schedule evaluated provides clinical benefit with low toxicity in frail, elderly patients affected by locally advanced HNSCC. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13688375
Volume :
74
Database :
Academic Search Index
Journal :
Oral Oncology
Publication Type :
Academic Journal
Accession number :
126042601
Full Text :
https://doi.org/10.1016/j.oraloncology.2017.10.004